Abstract: Sulfonamide derivatives, their physiologically tolerable salts and their prodrugs according to the present invention are vitronectin receptor antagonists and inhibitors of cell adhesion, as well as inhibit bone resorption by osteoclasts. These derivatives, salts and prodrugs are pharmaceutically active compounds useful in the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. Processes for the preparation of the sulfonamide derivatives according to the present invention, the use of these derivatives as pharmaceutically active ingredients, and pharmaceutical preparations comprising these derivatives also are disclosed.

Abstract: The use of an inhibitor of the Na+/H+ exchanger for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system. Inhibitors of the Na+/H+ exchanger are outstandingly suitable for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system; derivatives of guanidine are particularly highly suitable; cariporide (HOE 642) is especially suitable.

Abstract: Polyamide-oligonucleotide derivatives of the formula

Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Hs-ras gene and mRNA, and its use to specifically regulate, modulate, or inhibit expression of the Ha-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-ras gene, in particular in combination with chemotherapy and radiotherapy.

Abstract: Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described.

Abstract: Compounds of the formula I having the meanings of the substituents indicated in the claims are outstandingly active substances for the production of medicaments for the prophylaxis and for the therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal illnesses.

Abstract: Inhibitors of the sodium-hydrogen exchanger are suitable on their own or in combination with other classes of active compound for the production of a medicament for the treament of diseases which are caused by protozoa; thus of diseases which are caused by animal- and human-pathogenic protozoa, such as by intracellularly active parasites of the classes Apicomplexa and Zoomastigophorea, in particular trypanosomes, plasmodia (malaria pathogens), leishmanias, babesias and theilerias, cryptosporidiidae, sarcocystidae, amoebae, coccidia and trichomonads.

Abstract: The compounds 18.beta., 19.beta.-diacetyloxy-18.alpha., 19.alpha.-epoxy-3, 13(16), 14-clerodatrien-2-one (Esculentin A) and 18.beta., 19.beta.-diacetyloxy-18.alpha., 19.alpha.-epoxy-3, 12, 14-clerodatrien-2.beta.-isovaleryloxy-6.beta., 7.alpha.-diol (Esculentin B) obtained from plants belonging to the Samydaceae family, particularly Casearia esculenta, a process for their preparation, and their use in the manufacture of medicaments. The compounds are particularly useful as anti-inflammatory and/or anti-cancer agents.

Abstract: Novel isoquinoline-3-carboxamides of the formula I: ##STR1## in which R.sub.1 is hydrogen or chlorine, R.sup.2 is hydrogen, alkyl, alkoxy, chlorine, trifluoromethyl, hydroxyl, or benzyloxy which is optionally substituted, or fluoroalkoxy of the formula O--[CH.sub.2 ].sub.x --C.sub.f H.sub.(2f+1-g) F.sub.g, where x=0 or 1, f=1-5, and g=1 to (2f+1), R.sup.3 is hydrogen, alkyl, alkoxy, fluorine, chlorine, cyano, trifluoromethyl, hydroxyl, or benzyloxy which is optionally substituted, or fluoroalkoxy of the above formula, R.sup.4 and R.sup.5 are hydrogen, alkyl, fluorine, chlorine, bromine, trifluoromethyl, cyano, alkoxy, or fluoroalkoxy of the above formula, including the physiologically active salts, are strong prolyl-4-hydroxylase inhibitors which do not cause steatosis.

Abstract: A device for establishing a flange connection, having a bearing which can act on a first flange, a counter-bearing which can act on a second flange, and a connecting lever between the two bearings is described. The invention is distinguished by the fact that the connecting lever is a lever with a drawing element. The drawing element and the lever each have a first and second end. The drawing element's first end engages the bearing and its second end jointedly mounts in between the first and second ends of the lever. The counter-bearing has at least one contact location for the first end of the lever and a recess for the drawing element.

Abstract: The invention relates to a crystal modification of the compound of the formula I ##STR1## and the processes for the preparation of and use that crystal modifications 1. The invention is used for treating acute immunological episodes, such as sepsis, allergies, graft-versus-host and host-versus-graft-reactions, autoimmune diseases, in particular rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, liver fibrosis, cystic fibrosis, colitis, cancers, such as lung cancer, leukemia, ovarian cancer, sarcomas, Kaposi's sarcoma, meningioma, intestinal cancer, lymphatic cancer, brain tumors, breast cancer, pancreatic cancer, prostate cancer, or skin cancer.

Abstract: Compounds of the formula I, ##STR1## in which B, E, W, Y, Z, R, R.sup.2, R.sup.2a, R.sup.2b, R.sup.3, g and h have the meanings indicated in the specifications. The compounds of the formula I are valuable pharmaceutical active compounds, which are suitable, for example, for the therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders. The compounds of the formula I are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the therapy or prophylaxis of illnesses which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or are associated therewith, or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part.

Abstract: The present invention relates to a novel lantibiotic having the formula NH.sub.2 --R-actagardine, where NH.sub.2 --R is the radical of the amino acid alanine, which is formed by the microorganism Actinoplanes liguriae, DSM 11797 or Actinoplanes garbadiensis, DSM 11796 during fermentation, chemical derivatives of the lantibiotic, a process for its preparation and the use of the lantibiotics as pharmaceuticals.

Abstract: Compounds of the formula I ##STR1## having the meanings of the substituents indicated in the claims are outstandingly active substances for the production of medicaments for the prophylaxis and for the therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastro-intestinal region or for the treatment of diarrheal illnesses.

Abstract: Sulfonamide-substituted benzopyran derivatives, processes for their preparation, their use as a medicament, and pharmaceutical preparations comprising them Compounds of the formula I ##STR1## having the meanings of the substituents indicated in the claims are outstandingly active substances for the production of medicaments for the prophylaxis and for the therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal diseases.

Abstract: The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a nontoxic prodrug to give the toxic drug can be advantageously prepared in this way while retaining their respective functional properties.

Abstract: The invention relates to the preparation of the compound 4-(4-(4-(hydroxydiphenyl)-1-piperidinyl)-1-hydroxybutyl)-.alpha.,.alpha.-d imethylphenylacetic acid and its phosphorylated derivatives. These compounds can be prepared from .alpha.-(p-tert-butylphenyl)-4-(.alpha.-hydroxy-.alpha.-phenylbenzyl)-1-pi peridinylbutanol with the aid of fungi of the genus Cunninghamella or Absidia. The compounds according to the present invention can be used as pharmaceuticals for the treatment of allergic disorders, allergic rhinitis or asthma. Compounds of the formula II in which R.sup.1 is --CH.sub.2 --O--P(O)(OH).sub.2 and R.sup.2 is --OH; R.sup.1 is --CH.sub.3 and R.sup.2 is --O--P(O)(OH).sub.2 ; orR.sup.1 is --COOH and R.sup.2 is --O--P(O)(OH).sub.2 are produced by the process according to the present invention and are suitable as pharmaceuticals with antihistamine action.

Abstract: Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.

Abstract: The invention relates to the use of non-peptide bradykinin antagonists for the production of pharmaceuticals for the prevention and treatment of Alzheimer's disease. Suitable Compounds are non-peptide bradykinin antagonists which inhibit the actions of the Alzheimer's protein amyloid (.beta./A4) in isolated endothelial cells, such as for example, fused heterobicyclic fluoroalkyl derivatives.

Abstract: The invention relates to substituted propanolamine derivatives and their acid addition salts.Propanolamine derivatives of formula I, ##STR1## in which R.sup.1 to R.sup.8 have the meanings indicated in the specification, and their physiologically tolerable salts and processes for their preparation are described. The compounds are suitable, for example, as hypolipidemics.